This book covers foundational topics in the emerging field of radiopharmaceutical therapy. It is divided into three sections: fundamentals, deeper dives, and special topics. In the first section, the authors examine the field from a bird’s-eye view, covering topics including the history of radiopharmaceutical therapy, the radiobiology of radiopharmaceutical therapy, and the radiopharmaceutical chemistry of both metallic and non-metallic radionuclides. The second section provides a more in-depth look at specific radiotherapeutics. Chapters include broader discussions of the different platforms for radiopharmaceutical therapy as well as more focused case studies covering individual radiotherapeutics. The third and final section explores a number of areas for further study, including medical physics, artificial intelligence, in vivo pretargeting, theranostic imaging, and the regulatory review process for radiotherapeutics.
This book is the first of its kind and is useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology.
Arvustused
This is a substantial text extending to more than 550 pages, neatly formatted in the familiar Springer house style and liberally illustrated with photographs and diagrams in both colour and black and white. Individual chapters are sourced from a wide range of authors, in a concerted effort to capture the variation in practice internationally. This is very welcome . I would recommend this as a reference text for any nuclear medicine department . (Heather Williams, RAD Magazine, September, 2024)
There are no other books like this for those who want to learn or update themselves on the state of the art and the future of radiopharmaceutical therapy . I very strongly suggest this publication not only to nuclear physicians but also to all oncologists and other clinicians interested in the topic and to scientists and students who want to look for an extremely promising field of development for their future research or clinical practice. (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51 (4), 2024)
Preface.- Foreword.- Section
1. Fundamentals.
Chapter
1. Introduction:
The Case for Endoradiotherapy.
Chapter
2. The History of Endoradiotherapy.-
Chapter
3. The Nuclear Chemistry of Therapeutic Radionuclides.
Chapter
4.
The Production of Therapeutic Radionuclides.
Chapter
5. The Radiobiology of
Alpha Particles, Beta Particles, and Auger Electrons.
Chapter
6. The
Radiopharmaceutical Chemistry of Metallic Radionuclides.
Chapter
7. The
Radiopharmaceutical Chemistry of Non-Metallic Radionuclides.- Chapter
8.
Dosimetry in Endoradiotherapy.- Section
2. Deeper Dives.
Chapter
9.
Antibodies as Vectors for Endoradiotherapy.
Chapter
10. Case Study #1:
225Ac-Labeled IgG.
Chapter
11. Case Study #2: 131I-3F8.
Chapter
12. Case
Study #3: Antibody Fragments in Endoradiotherapy.
Chapter
13. Peptides as
Vectors for Endoradiotherapy.
Chapter
14. Case Study #4: LUTATHERA.
Chapter
15. Case Study #5: CXCR4.
Chapter
16. Case Study #6: JR11.
Chapter
17.
Small Molecules as Vectors for Endoradiotherapy.
Chapter
18. Case Study #7:
PSMA-617.
Chapter
19. Case Study #8: 223RaCl3.- Section
3. Special Topics.-
Chapter
20. Auger Emitters in Endoradiotherapy.
Chapter
21. In Vivo
Pretargeting.
Chapter
22. Theranostic Imaging and Endoradiotherapy.
Chapter
23. The Next Generation of Therapeutic Radionuclides.
Chapter
24. Artificial
Intelligence and Machine Learning.
Chapter
25. The Regulatory Review of
Radiotherapeutics: USA.
Chapter
26. The Regulatory Review of
Radiotherapeutics: Europe.
Chapter
27. The Regulatory Review of
Radiotherapeutics: Japan.- Chapter
28. Radiotherapeutics in the Nuclear
Pharmacy.
Chapter
29. The Future.
Lisa Bodei, MD, PhD is a nuclear medicine physician with extensive experience and expertise in therapeutic and diagnostic applications of nuclear medicine in oncology, particularly with theranostics and the application of genomic technology to further defining the efficacy of theranostics. She is the Director of the Targeted Radionuclide Therapy Section of the Molecular Imaging and Therapy Service in the Department of Radiology, MSKCC. She has authored more than 200 peer-reviewed publications and serves on the editorial boards of several scientific journals.
Jason S. Lewis, PhD, is the Emily Tow Chair, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility in the Department of Radiology, MSKCC. He heads a laboratory in the Sloan Kettering Institutes molecular pharmacology program and is a professor at the Gerstner Sloan Kettering Graduate School of BiomedicalSciences. He has published more than 300 papers, books, book chapters, and reviews on cancer imaging and therapy.
Brian M. Zeglis, PhD, received his scientific training at Yale University, the California Institute of Technology, and Memorial Sloan Kettering Cancer Center before starting his own lab at Hunter College of the City University of New York in 2015. His current research is focused on the synthesis, in vivo validation, and clinical translation of radiopharmaceuticals for the imaging and therapy of disease, with a particular emphasis on investigations at the intersection of radiochemistry and bioorthogonal chemistry.
Lisainfo e-raamatute kohta